For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | 2024-12-31 | ||
|---|---|---|---|---|
| Research and development | 10,212,782 | 10,791,058 | ||
| General and administrative | 8,497,920 | 9,559,534 | ||
| Total operating expenses | 18,710,702 | 20,350,592 | ||
| Loss from operations | -18,710,702 | -20,350,592 | ||
| Interest income, net | 244,394 | 357,096 | ||
| Foreign exchange (loss) gain, net | -833,673 | 119,120 | ||
| Loss before income tax | -19,299,981 | -19,874,376 | ||
| Income tax | 861,118 | 536,815 | ||
| Net loss | -20,161,099 | -20,411,191 | ||
| Basic EPS | -0.61 | -0.89 | ||
| Diluted EPS | -0.61 | -0.89 | ||
| Basic Average Shares | 32,968,336 | 22,881,415 | ||
| Diluted Average Shares | 32,968,336 | 22,881,415 | ||
Gain Therapeutics, Inc. (GANX)
Gain Therapeutics, Inc. (GANX)